Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced...
June 11, 2026 11:57 ET | Source: Human Continuum Inc.

Human Continuum Closes Over $5 Million in Seed Round Funding to Support the Development of its Integrated Exosome-Based Therapeutic Longevity Platform

Jupiter, F.L., June 11, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
June 09, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis

Matisse obtains FDA Fast Track Designation for isupartob sodium in sepsis. FDA's Fast Track is designed to get important new drugs to the patient earlier.
May 19, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium
May 14, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
May 07, 2026 07:34 ET | Source: Research and Markets

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "IgG4-Related Disease Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
April 16, 2026 03:30 ET | Source: Freya Biosciences

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
April 07, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
April 07, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires
April 01, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...